BioVector® MUG-Lucifer-met 人骨肉瘤细胞系 / MUG-Lucifer-met Human Osteosarcoma Cell Line

通用定义 / General Definition:BioVector® MUG-Lucifer-met 是一种高度专业化的、经过稳定转染的人类骨肉瘤 (Osteosarcoma) 细胞系。该细胞系源自 MUG-Lucifer 母系，其核心特征是稳定表达荧光素酶 (Luciferase) 报告基因，并且具有极高的转移 (Metastatic) 潜能。它被设计用于肿瘤生物学研究，特别是通过非侵入性生物发光成像 (BLI) 技术在活体动物模型中实时监测肿瘤的生长、血管生成以及向远端器官（如肺部）的转移过程。

BioVector® MUG-Lucifer-met is a highly specialized, stably transfected Human Osteosarcoma cell line. Derived from the MUG-Lucifer parental line, its core feature is the stable expression of the Luciferase reporter gene, coupled with high metastatic potential. It is designed for cancer research, specifically enabling the real-time monitoring of tumor growth, angiogenesis, and distal metastasis (such as to the lungs) in live animal models through non-invasive Bioluminescence Imaging (BLI).

BioVector® MUG-Lucifer-met 技术说明书 (Technical Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® MUG-Lucifer-met 人骨肉瘤细胞

• 组织来源： 骨 (Bone)

• 标记基因： 萤火虫荧光素酶 (Firefly Luciferase)

• 生长特性： 贴壁生长

• 细胞形态： 成纤维细胞样或多角形

2. 培养条件

• 基础培养基： BioVector® RPMI-1640 与 DMEM (1:1) 混合培养基

• 血清添加： 10% BioVector® 优质胎牛血清 (FBS)

• 筛选抗生素： 含有适量的博来霉素 (Zeocin) 或 嘌呤霉素 (Puromycin)（取决于具体的构建载体）以维持荧光素酶的表达。

• 培养环境： 37 摄氏度，5% CO2

• 传代比例： 1:3 至 1:6；建议在细胞汇合度达到 80%-90% 时传代。

3. 细胞应用

• 活体成像 (In vivo Imaging)： 通过向小鼠注射荧光素底物，实时观察肿瘤转移的动态过程。

• 转移机制研究： 探索导致骨肉瘤细胞向肺部转移的分子开关。

• 药物评价： 定量评估新型抗癌药物在抑制肿瘤转移方面的有效性。

4. 注意事项

• 信号验证： 在进行活体实验前，建议先通过体外荧光素酶活性检测 (Luciferase Assay) 验证细胞的信号强度。

• 生物安全性： 涉及转基因和人源肿瘤细胞操作，须符合生物安全二级 (BSL-2) 标准。

English Datasheet

1. General Product Information

• Product Name: BioVector® MUG-Lucifer-met Human Osteosarcoma Cell Line

• Tissue Source: Bone

• Reporter Gene: Firefly Luciferase

• Growth Properties: Adherent

• Morphology: Fibroblast-like or polygonal

2. Culture Conditions

• Basal Medium: BioVector® RPMI-1640 and DMEM (1:1) mixture

• Serum Supplement: 10% BioVector® Fetal Bovine Serum (FBS)

• Selection Antibiotic: Maintain with appropriate Zeocin or Puromycin (depending on the specific vector construct) to ensure stable Luciferase expression.

• Incubation: 37 degrees Celsius, 5% CO2

• Subculturing: 1:3 to 1:6 ratio; subculture when cells reach 80%-90% confluence.

3. Applications

• In vivo Imaging: Utilizing Bioluminescence Imaging (BLI) following D-luciferin injection to visualize the dynamic process of tumor metastasis in mice.

• Metastasis Research: Exploring the molecular switches that drive osteosarcoma cells to colonize the lungs.

• Drug Evaluation: Quantitatively assessing the efficacy of novel anti-cancer drugs in inhibiting metastatic progression.

4. Key Usage Notes

• Signal Validation: Before conducting in vivo studies, verify the signal intensity via an in vitro luciferase activity assay to ensure the reporter gene has not been silenced.

• Safety Protocols: As these are genetically modified human tumor cells, all handling must be performed under Biosafety Level 2 (BSL-2) conditions.

Note: For consistent bioluminescence signals, BioVector® recommends the use of its validated Luciferin substrates and high-grade FBS. Periodic STR profiling is suggested to maintain the integrity of the BioVector® MUG-Lucifer-met lineage.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net